Illumina Inc (ILMN) Files Form 4 Insider Selling : Jay T Flatley Sells 20,000 Shares

Illumina Inc (ILMN): Jay T Flatley , Chief Executive Officer of Illumina Inc sold 20,000 shares on Apr 12, 2016. The Insider selling transaction was reported by the company on Apr 14, 2016 to the Securities and Exchange Commission. The shares were sold at $170.14 per share for a total value of $3,401,014.00 according the SEC Form 4 Filing.

Company has been under the radar of several Street Analysts.Illumina is Downgraded by Canaccord Genuity to Hold while Lowering the Price Target of the company shares to $ 160 from a previous price target of $205 . Earlier the firm had a rating of Buy on the company shares. The Rating was issued on Feb 4, 2016.Illumina is Reiterated by Deutsche Bank to Hold while Lowering the Price Target of the company shares to $ 160 from a previous price target of $178 . The Rating was issued on Feb 3, 2016.

Currently the company Insiders own 2.2% of Illumina shares according to the proxy statements.In the past twelve weeks, the net percent change held by company insiders has changed by 13.8%.Institutional Investors own 98.69% of Illumina shares.During last six month period, the net percent change held by insiders has seen a change of 7.23%.

Illumina: On Monday, Apr 11, 2016 heightened volatility was witnessed in Illumina which led to swings in the share price. The shares opened for trading at $171.48 and hit $174.21 on the upside , eventually ending the session at $169.9, with a gain of 0.91% or 1.54 points. The heightened volatility saw the trading volume jump to 10,11,850 shares. The 52-week high of the share price is $242.37 and the company has a market cap of $24,975 M . The 52-week low of the share price is at $130.

Illumina Money Flow Index Chart

Illumina Inc. is engaged in production development of sequencing-and array-based solutions for genetic analysis. The Company offers integrated systems consumables and analysis tools for genetic analysis. It also manufactures sequencing and array platforms reagent kits and scanning equipment. Its customers include genomic research centers academic institutions government laboratories hospitals and reference laboratories pharmaceutical biotechnology agrigenomics commercial molecular diagnostic and consumer genomics companies. Its sequencing instruments perform a range of nucleic-acid analyses across a range of sample sizes. Its products and services are used for basic analysis and research including de novo sequencing genetic variation analysis epigenetics and targeted screening among others. It also provides products and services for other life sciences applied markets such as agrigenomics. It also offers Clarity Run Manager Clarity LIMS Silver and Clarity LIMS Gold.

Leave a Reply

Illumina - Is it time to Sell?

Top Brokerage Firms are advising their investors on Illumina. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.